MedPath
Found 38 clinical trials|View Analysis
Sort by:

Ivocizumab in the Treatment of Multiple Advanced Tumors

Phase 2
Recruiting
Conditions
Pheochromocytoma/Paraganglioma
Paget Disease, Extramammary
Renal Angiomyolipoma
Rhabdomyosarcoma
Perivascular Epithelioid Cell Tumor, Malignant
Sarcoma
Urachal Cancer
Neuroendocrine Cancer
Basal Cell Carcinomas
Sarcomatoid Carcinoma
Interventions
Drug: Ivocizumab
First Posted Date
2024-11-12
Last Posted Date
2024-12-27
Lead Sponsor
Fudan University
Target Recruit Count
400
Registration Number
NCT06683846
Locations
🇨🇳

Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors

Phase 1
Recruiting
Conditions
Small Cell Lung Cancer
Neuroendocrine Tumors
Interventions
Drug: BL-M14D1
First Posted Date
2024-07-17
Last Posted Date
2024-08-14
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
22
Registration Number
NCT06505824
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Phase 1
Recruiting
Conditions
Metastatic Neuroendocrine Prostate Cancer
Interventions
Drug: [68Ga]Ga-PSMA-11
Drug: [68Ga]GA-DOTA-TATE
Drug: [68Ga]Ga-NeoB
Drug: [177Lu]Lu-PSMA-617
Drug: [177Lu]Lu-DOTA-TATE
Drug: [177Lu]Lu-NeoB
Drug: Gonadotropin-releasing hormone (GnRH) analogues
Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,
Drug: GnRH antagonists
Drug: Antiemetics & antinauseants
Drug: Metoclopramide
First Posted Date
2024-04-23
Last Posted Date
2024-12-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
36
Registration Number
NCT06379217
Locations
🇬🇧

Novartis Investigative Site, Sutton, Surrey, United Kingdom

🇺🇸

Nebraska Cancer Specialists, Omaha, Nebraska, United States

🇺🇸

Memorial Sloan Kettering Cancer Ctr, New York, New York, United States

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Phase 1
Recruiting
Conditions
Neuroendocrine Cancer
Small Cell Lung Cancer
Interventions
Biological: ZG006
First Posted Date
2024-02-28
Last Posted Date
2024-12-16
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
105
Registration Number
NCT06283719
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Phase 1
Not yet recruiting
Conditions
Prostate Carcinoma
Stage III Prostate Cancer AJCC v8
Stage IV Prostate Cancer AJCC v8
Prostate Small Cell Neuroendocrine Carcinoma
Interventions
Drug: Bendamustine
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Bridge Therapy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Multigated Acquisition Scan
Biological: T-cell Receptor-engineered T-cells
Procedure: X-Ray Imaging
First Posted Date
2023-10-23
Last Posted Date
2024-10-17
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT06094842
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Phase 1
Recruiting
Conditions
Neuroendocrine Neoplasms
Small Cell Lung Carcinoma (SCLC)
Interventions
Drug: BI 764532
Drug: [89Zr]Zr-BI 764532
First Posted Date
2023-07-27
Last Posted Date
2024-11-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
12
Registration Number
NCT05963867
Locations
🇳🇱

Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands

A Study of PT217 in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phase 1
Recruiting
Conditions
Small Cell Lung Cancer (SCLC)
Large Cell Neuroendocrine Cancer (LCNEC)
Neuroendocrine Prostate Cancer (NEPC)
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Neuroendocrine Carcinomas (NEC)
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Interventions
First Posted Date
2022-12-15
Last Posted Date
2024-11-22
Lead Sponsor
Phanes Therapeutics
Target Recruit Count
203
Registration Number
NCT05652686
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 4 locations

Study of Oral MRT-2359 in Selected Cancer Patients

Phase 1
Recruiting
Conditions
NSCLC
Prostate Cancer
HR-positive, HER2-negative Breast Cancer
DLBCL
L-MYC and N-MYC Amplified Solid Tumors
SCLC
High Grade Neuroendocrine Cancer
NSCLC With High or Low L-MYC or N-MYC Expression
Interventions
First Posted Date
2022-09-19
Last Posted Date
2024-06-28
Lead Sponsor
Monte Rosa Therapeutics, Inc
Target Recruit Count
174
Registration Number
NCT05546268
Locations
🇺🇸

Honor Health Research Institute, Scottsdale, Arizona, United States

🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

🇺🇸

University of California San Diego, San Diego, California, United States

and more 16 locations

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Phase 2
Recruiting
Conditions
Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
First Posted Date
2022-07-22
Last Posted Date
2023-11-02
Lead Sponsor
Technische Universität Dresden
Target Recruit Count
67
Registration Number
NCT05470595
Locations
🇩🇪

Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany

🇩🇪

Krankenhaus St. Elisabeth und St. Barbara Halle (Saale) GmbH, Halle (Saale), Germany

🇩🇪

Charité - Universitätsklinikum Berlin Centrum 12, Medizinische Klinik, Berlin, Germany

and more 12 locations

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Prostate Cancer
Small Cell Neuroendocrine Carcinoma
Small Cell Carcinoma
Interventions
Drug: Apalutamide
Biological: Cetrelimab
First Posted Date
2021-06-15
Last Posted Date
2024-04-26
Lead Sponsor
Rahul Aggarwal
Target Recruit Count
2
Registration Number
NCT04926181
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath